ENPP1 Antibody Inhibitors - University of California
Summary
The European Patent Office published application EP4146706A1 for ENPP1 antibody inhibitors filed by The Regents of the University of California. The application claims anti-ENPP1 antibodies for therapeutic use, classified under IPC C07K 16/40, A61P 9/10, A61K 39/395, and C12N 15/63. The application designates all relevant European member states including AT, BE, DE, FR, GB, IT, NL, ES, PL, and 25 others.
What changed
EPO published patent application EP4146706A1 for ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) antibody inhibitors. The application claims compositions and methods using anti-ENPP1 antibodies for therapeutic applications, particularly cardiovascular indications based on A61P 9/10 classification. The application designates 31 European contracting states.
For biotechnology and pharmaceutical companies, this publication establishes a priority date and potential freedom-to-operate considerations for ENPP1-targeted therapies. Parties developing anti-ENPP1 antibody therapeutics or diagnostics should review the claims for potential infringement risks or licensing opportunities. The published international search report may provide initial assessment of patentability.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
INHIBITING ANTI-ENPP1 ANTIBODIES
Publication EP4146706A1 Kind: A1 Apr 08, 2026
Applicants
The Regents of the University of California
Inventors
DEB, Arjun
IPC Classifications
C07K 16/40 20060101AFI20240424BHEP A61P 9/10 20060101ALI20240424BHEP A61K 39/395 20060101ALI20240424BHEP C12N 15/63 20060101ALI20240424BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.